GenoGraph Diagnostics is an emerging UK diagnostics company focused on preventive diagnostics for lifestyle-related disease, beginning with prediabetes and Type 2 diabetes.
Current healthcare combines recognised clinical and anthropometric risk factors with established biochemical measures such as HbA1c and fasting plasma glucose. GenoGraph is investigating an additional biological layer: circulating molecular signatures associated with metabolic and gene-regulatory pathways.
Risk factors, BMI and other clinical information help identify people who may benefit from further assessment, while HbA1c, fasting plasma glucose and other established tests provide essential information about metabolic and glycaemic status.
GenoGraph is investigating whether risk-associated molecular changes could provide useful additional information earlier in the disease pathway.
The aim is more personalised preventive risk assessment alongside established clinical testing, not as a replacement for it.
Lifestyle and family history, age, BMI and other recognised clinical risk factors can help identify people who may benefit from further assessment.
Clinical / anthropometricHbA1c and fasting plasma glucose are established tests used to assess high risk of Type 2 diabetes; OGTT may also be used where appropriate.
BiochemicalEstablished clinical care includes glycaemic testing such as HbA1c, alongside blood pressure, lipids, BMI and other care processes.
Clinical monitoringEye screening, kidney assessment and foot surveillance help identify complications. Specialist investigations, including CT or MRI, may be used when clinically indicated.
Screening / investigationInvestigating circulating molecular signals associated with gene regulation, metabolic pathways and changing metabolic health.
Research layerEvaluating whether a carefully selected molecular biomarker panel could contribute to earlier, personalised susceptibility/risk assessment for prediabetes and Type 2 diabetes.
Preventive diagnostics researchFurther research may investigate how molecular information could complement established clinical measures as disease risk and metabolic dysfunction progress.
Long-term research interest includes molecular biomarkers associated with risk of microvascular and macrovascular complications.
Research-stage concept: This is a simplified conceptual pathway, not a fixed biological timeline. GenoGraph is investigating whether selected molecular biomarkers can provide useful additional risk information alongside established clinical assessment.
Official public-health data show a substantial population living with non-diabetic hyperglycaemia (often described as prediabetes) and Type 2 diabetes in England, including younger adults.
Around 5.7 million adults in England were estimated to have non-diabetic hyperglycaemia in 2021.
Estimated prevalence of non-diabetic hyperglycaemia among adults in England.
Just over 152,000 adults aged 19–39 in England had diagnosed Type 2 diabetes as of March 2024.
Eligible adults in this age range are routinely invited for an NHS Health Check, generally every five years.
Sources: OHID Diabetes Profile, April 2026 | NHS Health Check | OHID NHS Health Check Profile | Diabetes UK — Prediabetes
Crown copyright information reused under the Open Government Licence v3.0.
GenoGraph Diagnostics is an emerging UK diagnostics company developing a future-facing approach to preventive diagnostics for lifestyle-related disease.
Our current focus is prediabetes and Type 2 diabetes, with a longer-term research direction spanning cardiometabolic risk and related complications.
We are exploring blood-based molecular approaches that could contribute to earlier, more personalised understanding of health risk. The underlying preventive-diagnostics model is intended to be scalable across healthcare settings and, where evidence supports it, potentially applicable beyond the UK.
Scientific origin: The concept behind GenoGraph developed from postgraduate research in Medical Genomics focused on the molecular pathology of prediabetes and has continued towards further biomarker research and analytical development with academic scientific support.
GenoGraph is exploring advanced liquid-biopsy approaches as a foundation for future preventive diagnostics, investigating circulating molecular information associated with metabolic health, biological regulation and gene-regulatory pathways.
A minimally invasive blood sample can provide access to circulating biological information.
We investigate molecular information present within blood without relying on a single conventional measurement.
Selected biological signals can be studied using laboratory and computational approaches to investigate patterns associated with metabolic health.
Our research asks whether these molecular patterns could contribute to evidence-based, earlier and more personalised risk assessment.
Our public survey explores attitudes among UK adults aged 18–39 towards earlier preventive risk assessment and a future blood-based diagnostic approach.
Your opinion can help shape what comes next. Tell us what you think about advanced molecular biomarkers, preventive blood testing and earlier personalised risk information.
Open survey in new windowGenoGraph Diagnostics is working towards the research and clinical validation of new approaches to earlier health-risk assessment.
The Government's 10 Year Health Plan for England identifies a major shift “from sickness to prevention”, alongside greater use of innovation and personalised approaches to healthcare.
GenoGraph's research direction is aligned with this preventive vision. In the future, molecular risk information could be evaluated as a complementary layer alongside established primary-care risk assessment, high-risk monitoring and programmes such as the NHS Diabetes Prevention Programme.
10 Year Health Plan for England → · NHS Diabetes Prevention Programme → · Primary-care QOF guidance →
Prediabetes, Type 2 diabetes and related cardiometabolic conditions are global challenges. GenoGraph's longer-term vision is to develop an evidence-based preventive-diagnostics platform that could be adapted to different healthcare settings as the scientific and clinical evidence develops.
UK research and validation first. Wider application where future evidence, regulation and healthcare need support it.
The development of preventive diagnostics requires collaboration across biomedical research, laboratory science and healthcare — from biomarker discovery and analytical validation through to clinical evaluation and future implementation.
Opportunities for biomarker research, validation and translational collaboration.
Exploring future pathways towards clinical evaluation and healthcare implementation.
We welcome conversations with organisations interested in preventive diagnostics.
No. GenoGraph Diagnostics is currently in research and development. Its diagnostic technology is not yet commercially available.
The survey is being used to understand public attitudes towards earlier preventive health-risk assessment and new approaches to preventive blood testing.
Established tests such as blood glucose and HbA1c provide essential information about current glucose regulation. GenoGraph is investigating an additional biological layer: circulating molecular signatures associated with metabolic and gene-regulatory pathways. Our research asks whether these risk-associated molecular changes could provide useful additional information earlier in the disease pathway, alongside established clinical testing.
You can register your interest in hearing about future research opportunities. Registering interest does not enrol you in a study.
No. The current registration is only an expression of interest in future research opportunities and is not a diagnostic service or a research study.
For research, healthcare, partnership or general enquiries, contact GenoGraph Diagnostics.
genographdiagnostics@outlook.comWith your consent, this website uses Google Analytics and Meta Pixel to understand general website activity and engagement. Analytics are used to evaluate website traffic and interactions such as visits to the survey.
The GenoGraph preventive health survey is provided through Google Forms. Information submitted through the form is subject to Google's privacy practices. Survey responses are not intentionally transmitted to Meta through this website.
The volunteer-interest form collects only the information you choose to provide so that GenoGraph Diagnostics can contact you about future research opportunities. Please do not submit medical or health information through this form. Registering interest does not enrol you in a research study.
Optional analytics and advertising technologies are loaded only after you select Accept on the cookie notice. If you reject optional cookies, these website trackers are not loaded.
Development status: GenoGraph Diagnostics is currently in research and development. Its diagnostic technology is not yet commercially available. Information on this website describes the current research and development direction and should not be interpreted as medical advice or as a diagnostic service.